Franck MBA - Valneva SE Chief Officer
| VALN Stock | USD 4.00 0.30 6.98% |
Executive
Franck MBA is Chief Officer of Valneva SE ADR
| Age | 57 |
| Address | 6 rue Alain Bombard, Saint-Herblain, France, 44800 |
| Phone | 33 2 28 07 37 10 |
| Web | https://valneva.com |
Valneva SE Management Efficiency
The company has return on total asset (ROA) of (0.1059) % which means that it has lost $0.1059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0396) %, meaning that it created substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to drop to -0.29. At this time, Valneva SE's Other Current Assets are very stable compared to the past year. As of the 26th of November 2024, Intangible Assets is likely to grow to about 50.2 M, while Total Assets are likely to drop about 252.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eddie MBA | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 49 | |
Management Performance
| Return On Equity | -0.0396 | ||||
| Return On Asset | -0.11 |
Valneva SE ADR Leadership Team
Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Dequenne, Chief Officer | ||
| Frederic Jacotot, General IP | ||
| JuanCarlos MD, Chief Officer | ||
| Thomas Lingelbach, CEO President | ||
| Gerald Strohmaier, VP Resource | ||
| Peter Buhler, Chief Officer | ||
| Christian Taucher, Head Affairs | ||
| Perry Celentano, Interim Officer | ||
| Joshua Drumm, Vice Relations | ||
| Dipal Patel, Chief Officer | ||
| Susanne EderLingelbach, Head Operations | ||
| Laetitia BachelotFontaine, VP Relations | ||
| Petra Pesendorfer, Chief Officer | ||
| Katrin Dubischar, VP Vaccine | ||
| Franck MBA, Chief Officer | ||
| Hanneke Schuitemaker, Chief Officer |
Valneva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0396 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 389.74 M | ||||
| Shares Outstanding | 81.18 M | ||||
| Shares Owned By Institutions | 1.16 % | ||||
| Number Of Shares Shorted | 48.21 K | ||||
| Price To Book | 1.53 X | ||||
| Price To Sales | 2.20 X |
Pair Trading with Valneva SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Valneva SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Valneva SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Valneva Stock
Moving against Valneva Stock
| 0.56 | KZR | Kezar Life Sciences | PairCorr |
| 0.49 | RNXT | RenovoRx | PairCorr |
| 0.44 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.36 | NXGLW | NexGel Warrant | PairCorr |
| 0.33 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Valneva SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Valneva SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Valneva SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Valneva SE ADR to buy it.
The correlation of Valneva SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Valneva SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Valneva SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Valneva SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Valneva SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Valneva SE. If investors know Valneva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Valneva SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share 2.3 | Quarterly Revenue Growth 0.204 | Return On Assets (0.11) | Return On Equity (0.04) |
The market value of Valneva SE ADR is measured differently than its book value, which is the value of Valneva that is recorded on the company's balance sheet. Investors also form their own opinion of Valneva SE's value that differs from its market value or its book value, called intrinsic value, which is Valneva SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Valneva SE's market value can be influenced by many factors that don't directly affect Valneva SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Valneva SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Valneva SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valneva SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.